Romain Colle

Romain Colle

Auto-generated profile, based on publicly available information

Romain Colle

MOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
STSéverine Trabado
Séverine Trabado
AAAbdallah Al-Salameh
Abdallah Al-Salameh
VCVincent Croixmarie
Vincent Croixmarie
PMPerrine Masson
Perrine Masson
ECEmmanuelle Corruble
Emmanuelle Corruble
PCPhilippe Chanson
Philippe Chanson
Metabolomic approaches are increasingly used to identify new disease biomarkers, yet normal values of many plasma metabolites remain poorly defined. The aim of this study was to define the “normal” metabolome in healthy volunteers. We included 800 French volunteers aged between 18 and 86, equally distributed according to sex, free of any medication and considered healthy on the basis of their medical history, clinical examination and standard laboratory tests. We quantified 185 plasma metabolites, including amino acids, biogenic amines, acylcarnitines, phosphatidylcholines, sphingomyelins and hexose, using tandem mass spectrometry with the Biocrates AbsoluteIDQ p180 kit. Principal components analysis was applied to identify the main factors responsible for metabolome variability and orthogonal projection to latent structures analysis was employed to confirm the observed patterns and identify pattern-related metabolites. We established a plasma metabolite reference dataset for 144/185 metabolites. Total blood cholesterol, gender and age were identified as the principal factors explaining metabolome variability. High total blood cholesterol levels were associated with higher plasma sphingomyelins and phosphatidylcholines concentrations. Compared to women, men had higher concentrations of creatinine, branched-chain amino acids and lysophosphatidylcholines, and lower concentrations of sphingomyelins and phosphatidylcholines. Elderly healthy subjects had higher sphingomyelins and phosphatidylcholines plasma levels than young subjects. We established reference human metabolome values in a large and well-defined population of French healthy volunteers. This study provides an essential baseline for defining the “normal” metabolome and its main sources of variation.

1 February 2015 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
RCRomain Colle
Romain Colle
MCMarie Chupin
Marie Chupin
CCClaire Cury
Claire Cury
CVChristophe Vandendrie
Christophe Vandendrie
FGFlorence Gressier
Florence Gressier
ECEmmanuelle Corruble
Emmanuelle Corruble

9 October 2019 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
RCRomain Colle
Romain Colle
PMPerrine Masson
Perrine Masson
CVCéline Verstuyft
Céline Verstuyft
BFBruno Fève
Bruno Fève
EWErwan Werner
Erwan Werner
LBLaurent Becquemont
Laurent Becquemont

1 December 2016 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
RCRomain Colle
Romain Colle
DLDelphine de Larminat
Delphine de Larminat
SRSamuel Rotenberg
Samuel Rotenberg
FHFranz Hozer
Franz Hozer
PHPatrick Hardy
Patrick Hardy
ECEmmanuelle Corruble
Emmanuelle Corruble

Background:
Pioglitazone, a selective agonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), prescribed for the treatment of type 2 diabetes, could have antidepressant properties. However, its potential to induce remission of major depressive episodes, the optimal clinical target for an antidepressant drug, is a matter of concern. Indeed, only one out of four double-blind randomized controlled trials show higher remission rates with pioglitazone than with control treatments. Hence, the main aim of this study was to perform a meta-analysis of the efficacy of pioglitazone for the treatment of MDE, focusing on remission rates. Methods: Four double-blind randomized controlled trials, comprising 161 patients with an MDE, were included in this meta-analysis. Pioglitazone was studied either alone (one study) or as add-on therapy to conventional treatments (antidepressant drugs or lithium salts). It was compared either to placebo (three studies) or to metformin (one study). Remission was defined by a Hamilton Depression Rating Scale score <8 after treatment. Results: Pioglitazone could induce higher remission rates than control treatments (27% versus 10%, I2=17.3%, fixed-effect model: odds ratio [OR] =3.3, 95% confidence interval [95% CI; 1.4; 7.8], P=0.008). The OR was even higher in the subgroup of patients with major depressive disorder (n=80; 23% versus 8%, I2=0.0%; fixed-effect model: OR =5.9, 95% CI [1.6; 22.4], P=0.009) and in the subgroup of patients without metabolic comorbidities (n=84; 33% versus 10%, I2=0.0%; fixed-effect model: OR =5.1, 95% CI [1.5; 17.9], P=0.01). As compared to control treatments, results suggest six patients would need to be treated with pioglitazone in order to achieve the possibility of one more remission. Conclusion: Pioglitazone, either alone or as add-on therapy to conventional treatments, could induce remission of MDE, suggesting that drugs with PPAR-γ agonist properties may be true and clinically relevant antidepressants, even in patients without metabolic comorbidities.

15 December 2016 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
RCR. Colle
R. Colle
DLD. de Larminat
D. de Larminat
SRS. Rotenberg
S. Rotenberg
FHF. Hozer
F. Hozer
PHP. Hardy
P. Hardy
ECE. Corruble
E. Corruble
Introduction: Selective agonists of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ) are used for the treatment of type 2 diabetes. We reviewed their efficacy and safety for the treatment of major depression and the association of their potential antidepressant effects with changes in biomarkers of metabolism and inflammation. Methods: From 8 studies, 4 open-label trials, and 4 randomized controlled trials (RCT) (3 vs. placebo and 1 vs. metformin), 448 patients with major depression were included, of which 209 patients received PPAR-γ agonists (pioglitazone or rosiglitazone) for 6–12 weeks, either alone or in add-on therapy to conventional treatments. Results: PPAR-γ agonists have antidepressant effects in the 4 open-label studies and in 3 out of 4 RCT. No major adverse event was reported. Improvement in depression scores was associated with improvement in 3 biomarkers of insulin resistance (homeostatic model assessment [HOMA-IR], oral glucose tolerance test, and fasting plasma glucose) and 1 biomarker of inflammation (interleukin-6) among 21 biomarkers studied. Conclusion: PPAR-γ agonists may have antidepressant properties, which need to be assessed in further studies of major depressive episodes. * These authors contributed equally to this work. * These authors co-directed this work.

25 September 2015 in World Psychiatry
Verified
Journal Article
Open access
PDF file
ECEmmanuelle Corruble
Emmanuelle Corruble
KAKhalil El Asmar
Khalil El Asmar
STSeverine Trabado
Severine Trabado
CVCéline Verstuyft
Céline Verstuyft
BFBruno Falissard
Bruno Falissard
LBLaurent Becquemont
Laurent Becquemont